Eptinezumab for The Preventive Treatment of Migraine

References

• Nappi RE , BergaSL. Migraine and reproductive life. In: Handbook of Clinical Neurology.AminoffMJ, BollerF, SwaabDF ( Eds). Elsevier, Amsterdam, The Netherlands, 303–322 (2010).
   Google Scholar
• Lardreau E . A curiosity in the history of sciences: the words “megrim” and “migraine”. J. Hist. Neurosci.21(1), 31–40 (2012).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders 3rd Edition. Cephalalgia38(1), 1–211 (2018).
   PubMed Web of Science ®Google Scholar
• Zanchin G , DaineseF , MainardiF , MampresoE , PerinC , MaggioniF. Osmophobia in primary headaches. J. Headache Pain6(4), 213–215 (2005).
   PubMedGoogle Scholar
• Selby G , LanceJW. Observations on 500 cases of migraine and allied vascular headache. J. Neurol. Neurosurg. Psychiatry23, 23–32 (1960).
   PubMed Web of Science ®Google Scholar
• Lempert T , OlesenJ , FurmanJet al. Vestibular migraine: diagnostic criteria. J. Vestib. Res.22(4), 167–172 (2012).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , HollandPR , Martins-OliveiraM , HoffmannJ , SchankinC , AkermanS. Pathophysiology of migraine: a disorder of sensory processing. Physiol. Rev.97(2), 553–622 (2017).
   PubMed Web of Science ®Google Scholar
• Wei DY , Moreno-AjonaD , RentonT , GoadsbyPJ. Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic. J. Headache Pain20(1), 69 (2019).
   PubMedGoogle Scholar
• Karsan N , GoadsbyPJ. Biological insights from the premonitory symptoms of migraine. Nat. Rev. Neurol.14(12), 699–710 (2018).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ . The vascular theory of migraine--a great story wrecked by the facts. Brain132(Pt 1), 6–7 (2009).
   PubMedGoogle Scholar
• Messlinger K , FischerMJ , LennerzJK. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Keio J. Med.60(3), 82–89 (2011).
   PubMedGoogle Scholar
• Peroutka SJ . Neurogenic inflammation and migraine: implications for the therapeutics. Mol. Interv.5(5), 304–311 (2005).
   PubMedGoogle Scholar
• Johnson KW , SchausJM , DurkinMMet al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport8(9–10), 2237–2240 (1997).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , ClasseyJD. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience122(2), 491–498 (2003).
   PubMed Web of Science ®Google Scholar
• Schepelmann K , EbersbergerA , PawlakM , OppmannM , MesslingerK. Response properties of trigeminal brain stem neurons with input from dura mater encephali in the rat. Neuroscience90(2), 543–554 (1999).
   PubMed Web of Science ®Google Scholar
• Storer RJ , AkermanS , GoadsbyPJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol.142(7), 1171–1181 (2004).
   PubMed Web of Science ®Google Scholar
• Edvinsson L , GoadsbyPJ. Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia15(4), 272–276 (1995).
   PubMed Web of Science ®Google Scholar
• Schytz HW , OlesenJ , AshinaM. The PACAP receptor: a novel target for migraine treatment. Neurotherapeutics7(2), 191–196 (2010).
   PubMed Web of Science ®Google Scholar
• Amara SG , JonasV , RosenfeldMG , OngES , EvansRM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature298(5871), 240–244 (1982).
   PubMed Web of Science ®Google Scholar
• McCulloch J , UddmanR , KingmanTA , EdvinssonL. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc. Natl Acad. Sci. USA83(15), 5731–5735 (1986).
   PubMed Web of Science ®Google Scholar
• O’Connor TP , vander Kooy D. Enrichment of a vasoactive neuropeptide (calcitonin gene related peptide) in the trigeminal sensory projection to the intracranial arteries. J. Neurosci.8(7), 2468–2476 (1988).
   PubMed Web of Science ®Google Scholar
• Russell FA , KingR , SmillieSJ , KodjiX , BrainSD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev.94(4), 1099–1142 (2014).
   PubMed Web of Science ®Google Scholar
• Edvinsson L , WarfvingeK. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia39(3), 366–373 (2019).
   PubMed Web of Science ®Google Scholar
• Summ O , CharbitAR , AndreouAP , GoadsbyPJ. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain133(9), 2540–2548 (2010).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , EdvinssonL. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol.33(1), 48–56 (1993).
   PubMed Web of Science ®Google Scholar
• Olesen J , DienerHC , HusstedtIWet al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med.350(11), 1104–1110 (2004).
   PubMed Web of Science ®Google Scholar
• Jackson JL , CogbillE , Santana-DavilaRet al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS ONE10(7), e0130733 (2015).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , HollandPR. Migraine therapy: current approaches and new horizons. Neurotherapeutics15(2), 271–273 (2018).
   PubMed Web of Science ®Google Scholar
• Aurora SK , DodickDW , TurkelCCet al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia30(7), 793–803 (2010).
   PubMed Web of Science ®Google Scholar
• Diener HC , DodickDW , AuroraSKet al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia30(7), 804–814 (2010).
   PubMed Web of Science ®Google Scholar
• Charles JA . Roadblock to the only FDA-approved treatment for chronic migraine. Headache54(1), 169–170 (2014).
   PubMed Web of Science ®Google Scholar
• de Ru JA . Botulinum toxin-A is an effective and safe treatment for chronic migraine. Headache53(7), 1165–1167 (2013).
   PubMed Web of Science ®Google Scholar
• Silberstein SD , DodickDW , BigalMEet al. Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med.377(22), 2113–2122 (2017).
   PubMed Web of Science ®Google Scholar
• Dodick DW , SilbersteinSD , BigalMEet al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA319(19), 1999–2008 (2018).
   PubMed Web of Science ®Google Scholar
• Ferrari MD , DienerHC , NingXet al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, Phase IIIb trial. Lancet394(10203), 1030–1040 (2019).
   PubMed Web of Science ®Google Scholar
• Stauffer VL , DodickDW , ZhangQ , CarterJN , AilaniJ , ConleyRR. Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol.75(9), 1080–1088 (2018).
   PubMed Web of Science ®Google Scholar
• Skljarevski V , MatharuM , MillenBA , OssipovMH , KimBK , YangJY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase III randomized controlled clinical trial. Cephalalgia38(8), 1442–1454 (2018).
   PubMed Web of Science ®Google Scholar
• Detke HC , GoadsbyPJ , WangS , FriedmanDI , SelzlerKJ , AuroraSK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology91(24), e2211–e2221 (2018).
   PubMed Web of Science ®Google Scholar
• Dodick DW , AshinaM , BrandesJLet al. ARISE: a Phase III randomized trial of erenumab for episodic migraine. Cephalalgia38(6), 1026–1037 (2018).
   PubMed Web of Science ®Google Scholar
• Reuter U , GoadsbyPJ , Lanteri-MinetMet al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, Phase IIIb study. Lancet392(10161), 2280–2287 (2018).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , ReuterU , HallstromYet al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med.377(22), 2123–2132 (2017).
   PubMed Web of Science ®Google Scholar
• Tepper S , AshinaM , ReuterUet al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled Phase II trial. Lancet Neurol.16(6), 425–434 (2017).
   PubMed Web of Science ®Google Scholar
• Lionetto L , CurtoM , CisaleGYet al. Fremanezumab for the preventive treatment of migraine in adults. Expert Rev. Clin. Pharmacol.12(8), 741–748 (2019).
   PubMed Web of Science ®Google Scholar
• Lamb YN . Galcanezumab: first global approval. Drugs78(16), 1769–1775 (2018).
   PubMed Web of Science ®Google Scholar
• Markham A . Erenumab: first global approval. Drugs78(11), 1157–1161 (2018).
   PubMed Web of Science ®Google Scholar
• Ziegeler C , MayA. Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache60(2), 469–470 (2020).
   PubMed Web of Science ®Google Scholar
• Lundbeck . Vyepti (eptinezumab-jjmr): US prescribing Information. (2020). https://www.lundbeck.com/upload/us/files/pdf/Products/Vyepti_PI_US_EN.pdf
   Google Scholar
• Latham JKC , OjalaEet al. Characterization of the intrinsic binding features of three anti-CGRP therapeutic antibodies effective in preventing migraine: a comparative case study of ALD403, Ly-2951742, TEV-48125 [abstract no. PS74LB]. Headache56(8), 1398 (2016).
   Web of Science ®Google Scholar
• Dodick DW , GoadsbyPJ , SilbersteinSDet al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory Phase II trial. Lancet Neurol.13(11), 1100–1107 (2014).
   PubMed Web of Science ®Google Scholar
• Dhillon S . Eptinezumab: first approval. Drugs80(7), 733–739 (2020).
   PubMed Web of Science ®Google Scholar
• Baker B , SchaefflerB , BeliveauMet al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol. Res. Perspect.8(2), e00567 (2020).
   PubMed Web of Science ®Google Scholar
• Dodick DW , LiptonRB , SilbersteinSet al. Eptinezumab for prevention of chronic migraine: a randomized Phase IIb clinical trial. Cephalalgia39(9), 1075–1085 (2019).
   PubMed Web of Science ®Google Scholar
• Ashina M , SaperJ , CadyRet al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia40(3), 241–254 (2020).
   PubMed Web of Science ®Google Scholar
• Lipton RB , GoadsbyPJ , SmithJet al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology94(13), e1365–e1377 (2020).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society . The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia33(9), 629–808 (2013).
   PubMed Web of Science ®Google Scholar
• Lundbeck . Evaluate efficacy & safety of eptinezumab administered intravenously in subjects experiencing acute attack of migraine (RELIEF). https://clinicaltrials.gov/ct2/show/NCT04152083
   Google Scholar
• Ramon C , Cernuda-MorollonE , PascualJ. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Curr. Opin. Neurol.30(3), 281–286 (2017).
   PubMed Web of Science ®Google Scholar
• Lee MJ , LeeSY , ChoS , KangES , ChungCS. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J. Headache Pain19(1), 53 (2018).
   PubMedGoogle Scholar
• Lambru G , HillB , MurphyM , TylovaI , AndreouAP. A prospective real-world analysis of erenumab in refractory chronic migraine. J. Headache Pain21(1), 61 (2020).
   PubMed Web of Science ®Google Scholar
• Edvinsson L . CGRP antibodies as prophylaxis in migraine. Cell175(7), 1719 (2018).
   PubMed Web of Science ®Google Scholar
• Moreno-Ajona D , Perez-RodriguezA , GoadsbyPJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?Curr. Opin. Neurol.33(3), 309–315 (2020).
   PubMed Web of Science ®Google Scholar